• Structure-Based Discovery of NSP15 Inhibitors in SARS-CoV-2

  2026-05-20

  This study applies structure-based virtual screening and molecular dynamics to identify natural product inhibitors targeting the SARS-CoV-2 NSP15 endoribonuclease. The identification of thymopentin and oleuropein as potent NSP15 binders highlights promising leads for antiviral development and provides a blueprint for computational drug discovery against viral immune evasion mechanisms.

• Deracoxib: Selective COX-2 Inhibitor for Applied Cancer Rese

  2026-05-20

  Deracoxib empowers precise control of inflammation and tumor biology in veterinary research, offering cell-type-specific potency and workflow flexibility. This article delivers actionable guidance—from protocol optimization to troubleshooting—for leveraging Deracoxib in pain, inflammation, and canine cancer models, drawing on the latest experimental evidence.

• SEMA3E Drives Beige Adipocyte Differentiation via β-Catenin

  2026-05-19

  The reference study identifies SEMA3E as a critical promoter of beige adipocyte differentiation and thermogenesis through β-catenin signaling in mice. These findings illuminate a previously unappreciated regulatory axis in adipose tissue plasticity, with significant implications for metabolic disease research.

• Ceapin-A7: Selective ER Stress Blocker for Advanced UPR Stud

  2026-05-19

  Ceapin-A7 empowers researchers with precise, reproducible inhibition of the ATF6α pathway—unlocking new avenues in endoplasmic reticulum stress research and disease modeling. Its robust selectivity, combined with practical protocol enhancements, positions it as the benchmark chemical probe for dissecting unfolded protein response mechanisms.

• Cyclic di-GMP as an Antitoxin: Mechanisms of Biofilm Persist

  2026-05-18

  Liao et al. (2024) reveal a novel role for cyclic di-GMP as an antitoxin within a specialized toxin-antitoxin module that regulates genome stability and antibiotic persistence during early biofilm formation. These findings provide new mechanistic insights into biofilm resilience and identify molecular targets for future interventions against chronic bacterial infections.

• Thiamet G: Precision O-GlcNAcase Inhibition for Translationa

  2026-05-18

  This article unpacks the mechanistic underpinnings and translational promise of Thiamet G, a benchmark O-GlcNAcase inhibitor, for disease modeling and intervention. By integrating new evidence on O-GlcNAc-mediated regulation of ferroptosis and trophoblast biology with actionable assay guidance, we provide a strategic roadmap for researchers aiming to leverage protein O-GlcNAcylation in neurodegeneration, oncology, and maternal-fetal health.

• Applied Workflows for MK 0893: Glucagon Receptor Antagonist

  2026-05-17

  MK 0893 stands out as a potent, selective glucagon receptor antagonist, enabling precise dissection of GCGR signaling in both in vitro and in vivo models. This article details advanced experimental workflows, troubleshooting tips, and translational advantages that set MK 0893 apart for type 2 diabetes research.

• Monomethyl auristatin E (MMAE): Reliable Solutions for Cytot

  2026-05-16

  This article provides senior-scientist guidance for leveraging Monomethyl auristatin E (MMAE), SKU A3631, as a reproducible and potent cytotoxic agent in cell viability and proliferation assays. Drawing on validated data and common lab scenarios, it details best practices for protocol design, data interpretation, and vendor selection, ensuring that researchers achieve robust results with MMAE.

• Foretinib (GSK1363089) in Cancer Research: Optimized Workflo

  2026-05-15

  Foretinib (GSK1363089) empowers oncology labs to dissect tumor cell growth and metastasis with robust, reproducible inhibition of multiple tyrosine kinases. This guide delivers data-driven workflow enhancements, troubleshooting insights, and protocol specifics to accelerate translational cancer models.

• RCN2 Drives ESCC Metastasis and Cisplatin Resistance via PI3

  2026-05-15

  This study uncovers a novel mechanism by which RCN2 promotes metastasis and cisplatin resistance in esophageal squamous cell carcinoma (ESCC) through UBR5-mediated degradation of PPP2CA, leading to sustained PI3K-AKT pathway activation. These findings highlight RCN2 as a potential therapeutic target, informing new strategies for overcoming treatment resistance in aggressive ESCC.

• WNT5a/GSK3/β-catenin Axis Regulates FAP Adipogenesis in Musc

  2026-05-14

  This study elucidates how the WNT5a/GSK3/β-catenin axis governs adipogenic differentiation in skeletal muscle fibro/adipogenic progenitors (FAPs). By integrating pharmacological screening, high-dimensional mass cytometry, and transcriptomics, the research reveals a mechanistic pathway that shapes muscle regeneration and identifies potential targets for modulating pathological fat infiltration.

• CENP-E Inhibition and Centromere Integrity: Next-Gen Tools f

  2026-05-14

  This article provides a mechanistic and strategic analysis of GSK-923295, a potent CENP-E inhibitor, as a transformative tool for dissecting mitotic checkpoint fidelity and centromere function. Integrating the latest insights on centromere biology—particularly the interplay between CENP-E and centromere-maintaining factors such as CTCF—this piece bridges emerging basic science with actionable guidance for translational cancer researchers. The discussion contextualizes GSK-923295's advantages within the competitive landscape, references authoritative literature, and delivers a protocol-focused outlook for next-generation mitosis experiments.

• GSK J4 HCl: Redefining JMJD3 Inhibition for Translational Im

  2026-05-13

  This thought-leadership article presents a strategic, mechanistic synthesis for translational researchers exploring the power of GSK J4 HCl in epigenetic and inflammatory disorder research. Highlighting recent mechanistic findings, validated workflows, and clinical implications, the article positions GSK J4 HCl (from APExBIO) as a pivotal tool for dissecting histone H3K27 demethylation and modulating immune responses. By bridging experimental rigor with translational vision, it outlines actionable parameters and future horizons, while transparently benchmarking the compound against conventional approaches.

• K+ Channel Blockade Alters Renal Hemodynamics in Septic Rats

  2026-05-13

  This study investigates the impact of various potassium channel blockers on renal vascular responses to vasoactive agents in a rat sepsis model. The findings reveal that inhibition of specific K+ channels can exacerbate reductions in renal blood flow when combined with norepinephrine or phenylephrine, offering new insights for vascular biology and sepsis research.

• Prochlorperazine: Dopamine D2 Antagonist in Melanoma Workflo

  2026-05-12

  Prochlorperazine's impact as a dopamine D2 receptor antagonist extends far beyond antiemetic therapy, driving transformative advances in melanoma research through direct modulation of MITF and tyrosinase. This article unpacks experimental protocols, troubleshooting strategies, and cross-domain insights for researchers leveraging APExBIO's high-quality Prochlorperazine.

15618 records 1/1042 page Next 12345 下5页 Last page